Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Antithymocyte Globulin
76%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
50%
Cord Blood Transplantation
37%
Immune Reconstitution
32%
Individualized Dosing
29%
Pediatric
25%
Therapeutic Drug Monitoring
25%
Graft-versus-host Disease (GvHD)
20%
T Cell Reconstitution
20%
CD4+
18%
Serotherapy
17%
Pediatric Hematopoietic Stem Cell Transplantation
17%
Thymoglobulin
16%
Improved Survival
16%
Alemtuzumab
16%
Improved Outcomes
11%
T Cells
11%
Hazard Ratio
10%
Graft Failure
10%
Conditioning Regimen
10%
Population Pharmacokinetics (PopPK)
9%
Hematopoietic Stem Cell Transplantation
9%
Parachute
9%
Matched Unrelated Donor
9%
Busulfan
9%
Pediatric Oncology
8%
Population Pharmacokinetic Modeling
8%
T Cell Survival
8%
CD4+ T
8%
Pharmacodynamics
7%
Haemopoietic Stem Cell Transplantation
7%
Unrelated Cord Blood Transplantation
7%
Cohort Analysis
7%
Hematological Malignancies
7%
Human Herpesvirus 6 (HHV-6)
7%
High Risk
7%
Acute Lymphoblastic Leukemia
7%
High Dose
7%
Conditioning Regime
7%
Campath
7%
Pharmacogenetic Testing
7%
Phase I Trial
7%
Haploidentical
7%
Diffuse Cutaneous Systemic Sclerosis
7%
Precision Dosing
7%
Practical Guide
7%
Thymocytes
7%
Viremia
7%
Pharmacogenetics
7%
Pharmacist
7%
Immunology and Microbiology
Anti-Thymocyte Globulin
100%
Immune Reconstitution
57%
T Cell
55%
Cell Transplantation
53%
Hematopoietic Cell
46%
Cord Blood Stem Cell Transplantation
37%
CD4
28%
Allogeneic Hematopoietic Stem Cell Transplantation
25%
Pharmacokinetics
20%
Graft-Versus-Host Disease
20%
Alemtuzumab
15%
Overall Survival
11%
Human Herpesvirus 6
11%
Arm
10%
Blood Plasma
9%
Acute Graft Versus Host Disease
8%
CD19
8%
Pharmacodynamics
8%
Myeloid
8%
B Cell
8%
Leporidae
7%
Thymocyte
7%
Liquid Chromatography Tandem Mass Spectrometry
7%
Immunosuppression
7%
Filgrastim
7%
Engraftment
7%
Drug Megadose
7%
Viremia
7%
Stem Cell Transplantation
7%
Systemic Scleroderma
7%
Allogeneic Stem Cell Transplantation
7%
Autologous Hematopoietic Stem Cell Transplantation
7%
Globulin
7%
Chimeric Antigen Receptor T-Cell Therapy
7%
Drug Therapy
7%
T-Helper Cell
7%
Adenoviridae
7%
Natural Killer Cell
6%
Cytomegalovirus
5%
Epstein Barr Virus
5%
Umbilical Cord Blood
5%
Pharmacology, Toxicology and Pharmaceutical Science
Thymocyte Antibody
61%
Pharmacokinetics
31%
Graft Versus Host Reaction
18%
Therapeutic Drug Monitoring
17%
Globulin
16%
Melphalan
15%
Leporidae
15%
Pharmacodynamics
12%
Graft Failure
11%
Pharmacokinetic Modeling
10%
Overall Survival
10%
Alemtuzumab
9%
Busulfan
8%
Acute Lymphoblastic Leukemia
8%
Rhabdomyosarcoma
7%
Systemic Sclerosis
7%
Pharmacodynamic Modeling
7%
High Dose Chemotherapy
7%
Hematologic Malignancy
7%
Clinical Trial
7%
Controlled Clinical Trial
6%
Therapeutic Window
5%